Project Oncology

Host: Jacob Sands, MD Guest: Edith Mitchell, MD, MACP, FCPP, FRCP Appointed member to the President's Cancer Panel and Clinical Professor of Medicine at Thomas Jefferson University, Dr. Edith Mitchell, shares what the panel recommends to close gaps in cancer screening in the U.S.—with a focus on colorectal cancer—to improve access for all patients.

Host: Jacob Sands, MD Guest: Edith Mitchell, MD, MACP, FCPP, FRCP Widespread health disparities have led to challenges in colorectal cancer screening. What's causing these disparities—and what are some ways we can overcome these obstacles? To dive into this topic, Dr. Jacob Sands is joined by Dr. Edith Mitchell from Thomas Jefferson University to discuss these disparities and how they may be impacting clinical outcomes.

Host: Jacob Sands, MD Guest: Daniel Sessler, MD Our choice of anesthesia, whether it's regional or general, can have an effect on the outcome of our patients. But can this decision also contribute to cancer recurrence? To understand this, Dr. Jacob Sands sits down with renowned researcher in the anesthesia community, Dr. Dan Sessler, to learn more about his research on the impacts of general anesthesia.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua Richter, MD Here to share his perspective on the use of triplet therapy for the treatment of multiple myeloma is Dr. Joshua Richter. Dr. Richter shares a patient case and speaks with Dr. Charles Turck about why this treatment may be an option for some patients.

Host: Jacob Sands, MD Guest: Yasmin Jayasinghe, FRANZCOG, PhD Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.

Host: Jacob Sands, MD Guest: Yasmin Jayasinghe, FRANZCOG, PhD Cancer treatment can impact fertility outcomes for individuals throughout the U.S. as well as around the globe, which is why the emerging field of oncofertility is here to help male and female patients navigate their fertility options before and after their cancer treatments. So what can we learn from oncofertility services and efforts from other countries around the world? Joining Dr. Jacob Sands to share her global viewpoints on the field of oncofertility is Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital.

Host: Jennifer Caudle, DO Guest: Maryam Lustberg, MD, MPH Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.

Host: Jacob Sands, MD Guest: Suneeta Senapati, MD, MSCE Guest: Mindy Christianson, MD Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.

Host: Nabil F. Saba, MD, FACP Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.

Host: Jacob Sands, MD Guest: Joseph Tuscano, MD While lymphoma can sometimes be difficult to treat, emerging therapies and clinical developments are on the horizon. But could they help improve patient outcomes? Dr. Jacob Sands is joined by Dr. Joseph Tuscano, Physician and Professor of Hematology and Oncology at UC Davis Comprehensive Cancer Center to talk about updates in Lymphoma treatment.

Host: Jacob Sands, MD Guest: Shirish Gadgeel, MD Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.

Host: Jacob Sands, MD Guest: Benjamin Kann, MD Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.

Host: Jacob Sands, MD Guest: Brad McGregor, MD Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.

Host: Jacob Sands, MD Guest: Derek Raghavan, MD, PhD, FACP, FRACP CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the American Society of Clinical Oncology Annual Meeting.

Host: Jacob Sands, MD Guest: Millie Das, MD What are some of the latest advancements in small cell lung cancer? Dr. Jacob Sands discusses small-cell lung cancer treatment developments with Dr. Millie Das, a Clinical Associate Professor of Medical Oncology at Stanford University and Chief of Oncology at the Veteran’s Affairs Palo Alto Healthcare System.

Host: Jacob Sands, MD Guest: Mark Awad, MD, PhD What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.

Host: Jacob Sands, MD Guest: Mark Awad, MD, PhD Immunotherapy has led to impressive results, but when is it needed? Dr. Jacob Sands discusses the role of immunotherapy in managing lung cancer with Dr. Mark Awad, a thoracic medical oncologist, Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School.­

Guest: D. Ross Camidge, MD, PhD After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.

Guest: D. Ross Camidge, MD, PhD With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.

Host: Jacob Sands, MD Guest: Lori Pierce, MD, FASTRO, FASCO With only 3% of practicing oncologists identifying as Black, and less than 5% identifying as Latinx, how can we ensure these patient populations are equally represented in medical practice? Dr. Jacob Sands meets with ASCO’s current President, Dr. Lori Pierce, a Professor of Radiation Oncology and Vice Provost for Academic and Faculty Affairs at the University of Michigan, to discuss ASCO’s plan to increase quality in cancer care and research.